title: Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus.
abstract: BACKGROUND
  The aim of this study were to evaluate the feasibility and efficacy of chemotherapy using fluorouracil, adriamycin, and cisplatin (FAP) in patients with clinical stage II/III squamous cell carcinoma of the esophagus (SCCE).
  
  
  METHODS
  Forty patients were enrolled in the study. They received 30 mg/m(2) adriamycin and 70 mg/m(2) cisplatin on day 1, and 700 mg/m(2) 5-fluorouracil on days 1-5 every four weeks. Following two courses of chemotherapy, eligible patients underwent esophagectomy.
  
  
  RESULTS
  Twenty-one patients (53%) achieved partial response, and 27 patients underwent surgical resection (resection rate: 68%). Grade 3/4 toxicities developed: 7 patients (18%) with leukopenia, 23 (58%) with neutropenia. The three and five-year survival rates were 55% and 48%. Patients with surgical resection had better prognosis than those without resection, with a three-year survival rate of 68% vs. 25%.
  
  
  CONCLUSIONS
  FAP is effective and feasible and surgery may provide additional benefit for SCCE patients with FAP.
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan stamura@kanrou.net.
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Tamura
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeno
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Taniguchi
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Katsura
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ohmura
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kagawa
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Sakisaka
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.affiliation: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D016629:Esophagectomy; D004947:Esophagus / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil
keywords: Induction chemotherapy; adriamycin; cisplatin; combination chemotherapy; fluorouracil; metastatic esophageal cancer